KYNTRA BIO, INC. Debt Securities, Available-for-sale, Amortized Cost
KYNTRA BIO, INC. (KYNB) had Debt Securities, Available-for-sale, Amortized Cost of $44.76 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-13
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $44.76M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $58.33M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $61.23M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $3.03M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $44.76M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $58.33M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $61.23M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $3.03M 10-Q · filed 2025-11-10 |
| 2024-03-31 | $71.86M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $121.87M 10-K · filed 2025-03-17 |
| 2023-09-30 | $130.54M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $183.61M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $168.53M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $273.19M 10-K · filed 2024-02-26 |
| 2022-09-30 | $274.40M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $320.37M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $339.16M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $402.66M 10-K · filed 2023-02-27 |
| 2020-12-31 | $8.27M 10-K/A · filed 2022-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |